Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria

Liver Transplantation

Volumn 20, Issue 8, 2014, Pages 945-951

  Hameed, Bilal ^a   Mehta, Neil ^a   Sapisochin, Gonzalo ^a,b   Roberts, John P ^a   Yao, Francis Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE ASSOCIATION; END STAGE LIVER DISEASE; EXPLANT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGING; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; VASCULAR DISEASE; BLOOD; CARCINOMA, HEPATOCELLULAR; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STANDARDS; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; END STAGE LIVER DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905087935     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23904     Document Type: Conference Paper

References (32)

1. El-Serag HB,. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. Yang JD, Roberts LR,. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010; 24: 899-919.
3. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
4. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011; 11: 2362-2371.
5. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A,; for OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
7. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596.
8. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509.
9. Yao FY,. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8: 1982-1989.
10. Ioannou GN, Perkins JD, Carithers RL Jr,. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-1351.
11. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267.
12. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279.
13. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, et al.; for European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified Response Evaluation Criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108-1118.
14. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al.; for Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-984.
15. Mehta N, Yao FY,. Moving past «one size (and number) fits all» in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl 2013; 19: 1055-1058.
16. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR,. Systematic review: the prognostic role of alpha-fetoprotein following liver transplant for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35: 987-999.
17. Berry K, Ioannou GN,. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19: 634-645.
18. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C,. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
19. Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, Sun CL, et al. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011; 146: 26-33.
20. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
21. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S,. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362-2371.
22. Todo S, Furukawa H, Tada M,; for Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007; 13 (suppl 2): S48-S54.
23. Sotiropoulos GC, Lang H, Nadalin S, Neuhäuser M, Molmenti EP, Baba HA, et al. Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg 2007; 205: 661-675.
24. Edmondson HA, Steiner PE,. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
25. Bruix J, Sherman M,; for American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
26. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
27. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ III, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-827.
28. Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M,. Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 2011; 17 (suppl 2): S72-S80.
29. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137.
30. Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschênes M, et al. Pretransplantation α-fetoprotein slope and Milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013; 95: 228-233.
31. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY,. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013; 19: 1343-1353.
32. Roberts JP, Venook A, Kerlan R, Yao F,. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925-929.